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In clinical practice, simvastatin is usually used in the treatment of dyslipidemia patients and those at risk 
of or with established cardiovascular disease. However, previous studies have shown that simvastatin 
has the potential to affect glycemic parameters as it reportedly reduced insulin secretion and sensitivity. 
The exact mechanism by which simvastatin affects glycemia is still unknown, but previous studies 
have postulated the involvement of the glucose-insulin secretion mechanism. This review focuses on 
the effects of simvastatin, either alone or in combination with other lipid lowering agents, antidiabetics 
and antihypertensives, on glucose homeostasis. Some studies have reported that simvastatin might 
impair the levels of glucose metabolism markers in the blood while others have reported no effect or 
improvement in glycemia. 
Keywords: Simvastatin/effects. Glucose. Insulin secretion. Insulin sensitivity. Diabetes. Concurrent 
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INTRODUCTION
Statins or 3-hydroxyl-3 methylglutaryl co-enzyme A 
(HMG-CoA) reductase inhibitors are used worldwide to 
treat dyslipidemia and also as part of the management of 
patients who have high risk of developing or established 
cardiovascular events resulting from type 2 diabetes 
mellitus (T2DM) or hypertension (Grover, Luthra, Maroo, 
2014; Perreault et al., 2009). T2DM patients have a two- 
to four-fold increase in risk of cardiovascular disease as 
compared to the general population (Colhoun et al., 2004). 
In addition, these patients tend to have high levels of 
triglyceride, low levels of high-density lipoprotein (HDL) 
with smaller and denser low-density lipoprotein (LDL) 
particles that promote atherogenesis (Vijan, Hayward, 
2004). 
The key action of statins are by inhibition of 
the HMG-CoA reductase enzyme, hence reducing 
mevalonate synthesis and subsequently inhibits several 
other isoprenoid pathways as well as cholesterol synthesis 
(Gazzerro et al., 2012; Sirtori, 2014) (Figure 1). Currently, 
there are several types of statins available in the market, 
such as simvastatin, atorvastatin, lovastatin, fluvastatin, 
rosuvastatin and pravastatin. Cerivastatin has been 
withdrawn from the market after 52 deaths were reported 
due to kidney failure as a result of rhabdomyolysis 
(Furberg, Pitt, 2001). 
In the United States, data from the National Health 
and Nutrition Examination Survey 2011-2012 showed 
that among adults aged 40 years and above who were 
using lipid-lowering drugs, 83% were using a statin, 10% 
a combination of a statin and a non-statin and 7% non-
statin. Simvastatin was the most commonly used statin 
(42%), followed by atorvastatin (20.2%), pravastatin 
(11.2%), rosuvastatin (8.2%) and lovastatin (7.4%) (Gu 
et al., 2015).
Simvastatin or its brand name Zocor (Al-Foraih, 
Somerset, 2016) is one of the most commonly used statins 
because of its effectiveness in reducing LDL cholesterol 
levels, produces fewer adverse effects, and is more 
affordable compared with other statins. Simvastatin is a 
semi-synthetic derivative of lovastatin which is obtained 
from a fermented product of Aspergillus terreus (Manzoni, 
Rollini, 2002). Most patients are prescribed simvastatin 
at dosages of 10, 20, or 40 mg/day. However, the use of 
simvastatin at 80 mg/day is restricted because of a high 
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risk of muscle injury (FDA, 2011). 
The efficacy of simvastatin in reducing the risk, 
morbidity, and mortality of cardiovascular events has been 
demonstrated in various studies, such as the Scandinavian 
Simvastatin Survival Study (Pedersen et al., 1998), 
the Heart Protection Study (Heart Protection Study 
Collaborative Group, 2002), the Study of the Effectiveness 
of Additional Reduction in Cholesterol and Homocysteine 
(SEARCH) Collaborative Group (Meade et al., 2010) and 
others (Ceriello, 2002; Dobs et al., 2008; Foody et al., 
2008). However, some studies have reported association 
between statins and glycemia, but such effects are 
controversial and conflicting ranging from adverse, neutral 
to beneficial. In diabetics, simvastatin has been shown 
to worsen glycemic control and insulin secretion (Bellia 
et al., 2012), improve insulin resistance (Paolisso et al., 
2000) or to have no effect on glucose levels (Farrer et al., 
1994; Szendroedi et al., 2009).
In terms of solubility, statins can be classified into 
water-soluble (hydrophilic) and lipid soluble (lipophilic). 
Atorvastatin, fluvastatin, lovastatin, and simvastatin are 
lipophilic statins, while rosuvastatin and pravastatin are 
hydrophilic statins (Igel, Sudhop, Bergmann, 2002). 
For lipophilic statins, it can diffuse through the plasma 
membranes of extrahepatic cells (for example beta cells, 
adipocytes and skeletal muscle cells), which can result 
in a diabetogenic effect (Aiman, Najmi, Khan, 2014; 
Schachter, 2005). As simvastatin is a lipophilic statin, it 
has the potential to reduce insulin secretion and sensitivity 
(Koh et al., 2009). 
Effect of simvastatin on glucose metabolism: 
in vitro studies 
The exact mechanisms underlying the effect of 
simvastatin on glycemia are still unknown. However, 
previous studies have implicated the inhibition of 
glucose-stimulated insulin secretion. Several experimental 
studies have indicated how simvastatin affects glucose 
metabolism (Figure 2). 
The effect of statins (simvastatin, simvastatin acids, 
and pravastatin) on β cell function has been investigated 
in rat pancreatic β cells. Cytosolic calcium (Ca²+) 
concentration is an important component in the regulation 
of pancreatic β cells (De Marchi et al., 2014). A reduction 
in the cytosolic Ca2+ concentration leads to impairment 
of insulin secretion. In the study by Yada et al. (1999) 
has demonstrated that simvastatin inhibited β cell L-type 
Ca2+channels and reduced insulin secretion but pravastatin 
did not. After administration of simvastatin for 20 seconds, 
L-arginine and potassium chloride-induced insulin release 
were inhibited (Yada et al., 1999).
The mechanisms by which simvastatin impairs 
insulin secretion have been elucidated using mouse islet 
FIGURE 1 - Inhibition of the cholesterol synthesis pathway by statins.
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β cell lines, MIN6. Compared to normal control cells, 
simvastatin significantly inhibited insulin secretion in a 
dose-dependent manner. The inhibition of insulin secretion 
was indirectly caused by reduced levels of glucose 
transporter 2 (GLUT2). Simvastatin reduced the adenosine 
triphosphate (ATP) levels in MIN6 cells, increased the 
ATP-sensitive potassium channel (KATP) current and 
reduced the L-type - Ca2+ current. Simvastatin may 
also reduce insulin secretion by increasing the rectifier 
potassium channel (Kir6.2) current while simultaneously 
decreasing the voltage-dependent Ca2+ channel 1.2 
(Cav1.2) current, which leads to inhibition of membrane 
cell depolarization and inhibition of calcium influx (Zhou 
et al., 2014).
Glycemic effect of simvastatin: human data
Simvastatin has been reported to increase plasma 
glucose levels and reduce insulin sensitivity. A few studies 
have measured the effect of simvastatin treatment on 
glucose homeostasis (Table I). In a study by Koh et al. 
(2008) reported that simvastatin improved flow-mediated 
dilation, but reduced adiponectin levels and insulin 
sensitivity in hypercholesterolemia patients (Koh et al., 
2008). Patients who were on simvastatin 80 mg/day had a 
7% increase in mean plasma glucose levels after 2 months 
of treatment. Meanwhile, those who were on simvastatin 
10, 20, 40, or 80 mg/day had increased insulin secretions 
relative to the baseline after 2 months of treatment, 
which is indicative of deterioration in insulin sensitivity. 
The same study also demonstrated that there was a 
slight reduction in insulin sensitivity in the simvastatin-
treated group, as measured using the quantitative insulin 
sensitivity check index (QUICKI) (Koh et al., 2008). A 
separate study by the same authors showed significant 
reductions in insulin sensitivity and plasma adiponectin 
levels in hypercholesterolemia patients after taking 
simvastatin 20 mg/day for 2 months. However, there 
were no significant differences in insulin or glucose levels 
compared to baseline (Koh et al., 2015). 
A study in which patients were selected randomly 
to receive either simvastatin 20 mg/day or rosuvastatin 
20 mg/day showed that there was no effect of simvastatin 
on insulin sensitivity and glycemic control after 4 weeks 
of treatment (Bellia et al., 2010). However, another study 
by the same authors reported that the simvastatin and 
rosuvastatin treatments worsen fasting blood glucose 
(FBG) and A1C levels after 12 months without affecting 
insulin sensitivity (Bellia et al., 2012). On the same note, a 
study by Sen et al. (2002) found that in simvastatin group, 
A1C levels were significantly increased at follow-up at 90 
and 180 days compared to day 1 (Sen et al., 2002). 
Conversely, some studies have reported a lack of 
association between simvastatin treatment and blood 
glucose levels. After 90 days of simvastatin treatment, 
the homeostasis model assessment - insulin resistance 
(HOMA-IR) values and FBG levels remained unchanged 
in patients with isolated hypercholesterolemia, even 
though there were improvements in plasma lipid levels 
(Krysiak, Okopien, 2013a). As for T2DM patients, some 
studies have reported no significant changes in glucose 
parameters after simvastatin treatment (Farrer et al.,1994; 
Hwu et al., 1999). Szendroedi et al. (2009) reported that 
there was no effect of simvastatin on insulin sensitivity, 
fasting insulin levels or HOMA-B levels (Szendroedi et 
al., 2009). In addition, a study by Hydrie et al. (2007) 
found after receiving simvastatin for 3 months, there were 
no significant differences in HOMA-IR values compared 
to baseline. However, 20 patients with T2DM who were 
having insulin resistance with HOMA-IR values of more 
than 2.8 at the beginning of the study demonstrated 
improvements in insulin sensitivity after receiving 
simvastatin (Hydrie et al., 2007). 
Simvastatin and new-onset Diabetes
The Heart Protection Study has suggested that there 
was no association between simvastatin use and new-onset 
diabetes, although previous studies have reported that statins 
FIGURE 2 – Previous experimental findings on the effect of 
simvastatin on glucose-insulin secretion.
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TABLE I - The effect of simvastatin on glucose metabolism markers in human data
Study design Country Subjects N Mean follow-up Method
Outcome (compared with baseline)
A1C Glucose Insulin Insulin sensitivity Adiponectin
Randomized 
, double 
blind, placebo 
controlled 
parallel study 
(Koh et al., 
2008)
Korea Hypercholes-terolemia 156 2 months
Each 32 patients given 
either placebo, SIM 10, 
20, 40 or 80 mg/day
Not 
measured
SIM 80 mg/
day  increase 
glucose level 
SIM 10, 20, 
40 and 
80 mg/day 
increase 
insulin level 
SIM 10,20, 
40 and 80 
mg/day 
reduce insulin 
sensitivity 
SIM 10, 20, 40 
and 80 mg/day 
decrease 
plasma 
adiponectin
Randomized 
, single-blind 
, placebo-
controlled , 
parallel study 
(Koh et al., 
2015)
Korea Hypercholes-terolemia 203 2 months
Each 51 patients receive 
either placebo, EZE 
10 mg + SIM 10 mg 
(Vyto10), EZE 10  mg + 
SIM 20 mg (Vyto20)  or 
SIM 20 mg  alone once 
daily
SIM 20 mg no 
different
SIM 20 
mg no 
different 
SIM 
20 mg 
group not 
significant 
change 
insulin 
level 
SIM 20 
mg group 
reduce the 
insulin 
sensitivity
SIM 20 
mg group 
significantly 
reduce 
plasma 
adiponectin 
level  
Randomized, 
single-blind, 
parallel 
intervention 
study (Bellia 
et al., 2010)
Italy
Patients with 
middle aged  
with T2DM and 
mild treated 
dyslipidemia
29 4 weeks 
Patients receive either 
ROS 20 mg/day or SIM 
20 mg/day
Not 
measured
No effect 
in both 
groups 
No effect 
in both 
groups
No effect 
in both 
groups
No effect in 
both groups
Randomized, 
single-blind 
with two period 
(Bellia et al., 
2012)
Italy Well controlled T2DM patients 27 12 months
Patients receive either  
ROS 20 mg/day or  SIM 
20 mg/day for 6 months 
and switch the treatment 
for following next 6 
months
Both groups 
worsen A1C 
Both 
groups 
increase 
FBG 
No 
changes 
No effect 
in both 
groups
Not 
significant 
increase 
Double blind 
randomized  
placebo-
controlled study 
(Sen et a.l., 
2002) 
India 
T1DM and T2DM 
with diabetic 
retinopathy
50 180 days
Patients receive 
either SIM 20 mg/day 
or placebo
A1C in SIM 
group increase 
throughout the 
follow-up at 
90 days and 
180 days 
No 
significant 
changes in 
FBG 
No 
significant 
changes
Not 
measured
Not 
measured
Randomized 
study 
(Tsutamoto 
et al., 2009)
Japan
Non-ischemic 
chronic heart 
failure
71 2.2 ± 0.15 years
 Patients receive either 
SIM 5 mg/day 
(n = 35)  
or ROS 2.5 mg/day
(n = 36)
Slightly 
increase in 
SIM  group 
& decrease in 
rosuvastatin 
group 
Not 
measured
Not 
measured
Not 
measured
No changes 
in SIM 
group but 
increase in 
ROS group
Randomized, 
case-control 
study (Krysiak, 
Okopien, 
2013a)
Polland
Isolated 
hypertriglyce ri-
demia
39 3 months Patients receive placebo or SIM 40 mg/day
Not 
measured
Both 
groups not 
significant
Not 
measured
Both 
groups not 
significant
Not 
measured
Double blind 
placebo 
controlled 
study (Farrer 
et al., 1994)
United 
Kingdom
Patients 
with T2DM 
dyslipidemia and 
mild hypertriglyce-
ridemia
70 6 months Patients randomized to receive placebo or SIM
No 
significant 
changes
No 
significant 
changes
No 
significant 
changes
Not 
measured
Not 
measured
Randomized, 
double-blind, 
placebo-
controlled and 
two-period 
crossover study 
(Hwu et al., 
1999)
Taiwan
Patient T2DM  
with hypercholes-
terolemia
19 6 months
Patients receive either 
SIM 20 mg/day or 
placebo for 3 months and 
exchange the treatment 
for subsequent 3 months
No effect 
in SIM 
group
No effect 
in SIM 
group
Not 
measured
No effect 
in SIM 
group
Not 
measured
Randomized , 
double-blind, 
placebo-
controlled, 
single 
center study 
(Szendroedi et 
al., 2009)
German
Non-obese T2DM 
patients 30 2 months
Patients given placebo or 
SIM 80 mg/day
No significant 
changes
Not 
measured
No 
significant 
changes 
No 
significant 
changes
Not 
measured
Randomized, 
case control 
study (Hydrie et 
al., 2007)
Pakistan Patients with T2DM 100 3 months
50 patients receive SIM  
40 mg/day as case and 
50 patients as control 
group
Not measured
No 
significant 
changes 
No 
significant 
changes
No 
significant 
changes
Not 
measured
Abbreviation: SIM (simvastatin); EZE (ezetimibe); ROS (rosuvastatin); T1DM (type 1 diabetes mellitus); T2DM (type 2 diabetes mellitus). Significant value p < 0.05
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might induce the new-onset of diabetes. Among 14, 573 
subjects without diabetes at study entry, it was noted that 
there was no significant difference in number of new-onset 
diabetes between the simvastatin group (4.6%) and the 
placebo group (4.0%). After follow-up for 4.6 years, among 
1087 subjects who had diabetes at study entry, there was no 
significant difference in increased A1C among treatment 
groups (Heart Protection Study Collaborative Group, 2003). 
However, the Study of Effectiveness of Additional 
Reductions in Cholesterol, Homocysteine (SEARCH) 
trial showed that there was a slight increase in new-onset 
diabetes with high dose simvastatin, 80 mg/day (11.6%) 
compared to low dose, simvastatin 20 mg/day (10.9%) 
(Armitage et al., 2010) (Table II). 
Effect of simvastatin and concurrent medications 
on glycemic control
Certain patients, like those with metabolic syndrome 
and T2DM, require combinations of lipid lowering drugs 
because the use of simvastatin alone may fail to result in 
optimal lipid targets. Fenofibrate and niacin are the lipid 
lowering agents which are most often prescribed together 
with statins (Cannon, 2008). However, these concomitant 
drugs may increase the risk of drug-drug interaction with 
regards to glycemic effects, as shown in Table III.
Niacin therapy is known to have beneficial effects in 
patients with dyslipidemia as it increases HDL cholesterol 
levels and at the same time reduces triglyceride and LDL 
cholesterol levels. However, niacin has the potential to 
increase blood glucose levels (Bays, 2008; Sazonov et 
al., 2013; Zhao et al., 2004). In a study by Vittone et al. 
(2007), it was found that three years’ usage of niacin in 
combination with simvastatin had a slight adverse effect 
on glycemic control, whereby FBG was increased by 3%, 
fasting insulin was elevated by 19%, and insulin sensitivity 
was reduced by 10% compared to baseline results (Vittone 
et al., 2007). As such, even though niacin when used alone 
or in combination with a statin gives beneficial effects to 
T2DM patients (in terms of achievement of target lipid 
levels), glucose levels should be monitored in those who 
are on long-term treatment (Ding, Li, Wen, 2015).
In general, fibrates reduce plasma triglyceride levels 
by 30-50%, reduce LDL cholesterol levels by up to 20% 
TABLE II - Comparison of relative risk of new-onset diabetes with simvastatin use
Study’s Name Subjects Mean follow-up Method
Relative risk of NOD 
(95% CI)
Heart Protection Study 
(HPS)  
(Heart Protection 
Study Collaborative 
Group, 2003)
Patients with diabetes 
(5, 963) and patient  
occlusive arterial disease 
with non-diabetes 
(14, 573)
4.6 years
Patients randomized 
to receive either 
simvastatin 40 mg/day 
or matching placebo
Simvastatin vs. placebo 
1.14 (0.98-1.33)
Study of Effectiveness 
of Additional Reductions 
in Cholesterol and 
Homocysteine 
(SEARCH) (Armitage 
et al.,2010)
12, 064 patients with 
history of myocardial 
infarction 
6.7 years
Patients randomized to 
receive either low dose, 
simvastatin 20 mg 
(6,033 patients) or high 
dose 80 mg 
(6,031 patients)  
daily
High dose vs. low dose 
1.07 (0.95-1.19)
Abbreviation: NOD (New-onset diabetes)
TABLE III - Summary effects of simvastatin in combination with other lipid lowering medications based on previous studies
Authors Combination lipid lowering drug Finding (compared to baseline)
(Vittone et al., 2007) Niacin + simvastatin ↑ FBG, ↑ fasting insulin, 
↓ insulin sensitivity
(Derosa et al., 2009) Fenofibrate + simvastatin ↓ A1C, no significant changes in fasting glucose, fasting insulin, post-prandial glucose 
(Koh et al., 2015) Ezetimibe + simvastatin (Vyto 10) ↓ Fasting insulin, ↑ adiponectin, 
↑ insulin sensitivity
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and increase HDL cholesterol levels by 5-15% (Chapman, 
2003; National Cholesterol Education Program, 2002). In 
contrast to niacin, fenofibrate is often used with simvastatin 
in T2DM patients to achieve target lipid levels because 
fibrates do not lead to the worsening of blood glucose 
levels. The simvastatin-fenofibrate combination has been 
shown to be significantly more effective than simvastatin 
alone (Grundy et al., 2005). A study whose objective 
was to determine the effectiveness of fenofibrate alone, 
simvastatin alone and both drugs combined recruited 241 
patients with T2DM and dyslipidemia who have never 
been prescribed lipid lowering medications before. The 
patients were divided into three groups; one received 
fenofibrate 145 mg/day, another received simvastatin 40 
mg/day, and the remaining received a combination of the 
aforementioned drugs. Glucose and lipid profiles were 
evaluated at baseline, 6 and 12 months. As expected, 
total cholesterol, LDL cholesterol, and triglyceride levels 
decreased while HDL cholesterol increased. In patients 
treated with simvastatin alone, there was no difference 
between baseline A1C levels and those at 12 months. 
However, A1C levels were significantly decreased in the 
other two groups. After 6 and 12 months of treatment, 
there were no significant differences in FBG, postprandial 
glucose and fasting plasma insulin levels in all three 
groups (Derosa et al., 2009). 
Ezetimibe is a LDL cholesterol-lowering drug that 
acts by inhibiting the absorption of dietary cholesterol in 
the small intestine (Ahmed, Byrne, 2010). In a randomized 
double-blinded study, T2DM patients received stable 
doses of thiazolidinediones (rosiglitazone 2-8 mg/day 
or pioglitazone 15-45 mg/day) for at least 3 months 
and simvastatin 20 mg/day for 6 weeks prior to the 
study. Patients were then randomized to receive either 
ezetimibe 10 mg/day (n=104) or an increased dose of 
simvastatin 40 mg/day (n=110) for 24 weeks. The results 
showed that there were no significant differences between 
treatment methods with regards to FBG, fasting plasma 
insulin, and A1C levels. However, LDL cholesterol 
levels were reduced to a greater extent in patients who 
received additional ezetimibe 10 mg/day or simvastatin 
20 mg/day compared to those who received a doubled 
simvastatin dose (40 mg/day) (Gaudiani et al., 2005). 
Another study found that 2 months after the administration 
of combined simvastatin 10 mg and ezetimibe 10 mg 
(Vyto10) to patients with dyslipidemia, fasting insulin 
was significantly reduced while plasma adiponectin and 
insulin sensitivity were increased relative to the baseline 
(Koh et al., 2015). 
P a t i e n t s  w i t h  T 2 D M  m a y  h a v e  m u l t i p l e 
comorbidit ies that  necessitate the concomitant 
administration of statins with other drugs. Clinical 
studies have shown that a combination of simvastatin with 
metformin and pioglitazone results in improved glycemic 
control (Table IV). In T2DM patients, metformin is the 
recommended first-line pharmacological treatment after 
TABLE IV - The effect of concurrent medications in combination with simvastatin (oral antidiabetic agents)
Concurrent 
medication Subjects Country N
Mean 
follow-up 
(months)
Method
Outcome
Fasting 
glucose
Fasting 
insulin A1C
Insulin 
sensitivity Adiponectin
Metformin 
(Krysiak, 
Okopien, 
2013b)
IFG patients 
treated with 
simvastatin at 
least 3 month
Poland 48 3 Patient randomized 
received MET  
or placebo for the 
next following 
90 days
MET + 
SIM group 
approach  near 
significant 
decrease FBG 
compared 
to before 
randomization 
(p = 0.071)
Not 
measured
MET + 
SIM group 
significant 
reduce  A1C 
compared to 
baseline and 
placebo (p < 
0.001)
MET + SIM 
group had 
improvement 
in HOMA-IR 
(p < 0.001) 
Not 
measured
Pioglitazone 
(Forst et al., 
2007)
Non-diabetic 
patients with 
cardiovascular 
risk 
Germany 125 3 Patients randomized 
received PIO + 
placebo, PIO + SIM, 
SIM + placebo.  
 
Treatment started 
with PIO 30 mg 
or and SIM 20 
mg. After 2 weeks 
increase dosage to 
PIO 45 mg or and 
SIM 40 mg
FBG reduce in 
group treated 
with PIO and 
PIO + SIM 
Reduce in 
group 
treated with 
PIO and 
PIO + SIM 
Not 
measured
HOMA score 
improved in 
group treated 
with PIO and 
PIO + SIM 
Adiponectin 
increase 
in PIO and 
PIO + SIM 
group, while 
reduce in  
group treated 
with SIM  
Abbreviation: MET (metformin); SIM (simvastatin); PIO (pioglitazone)
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lifestyle interventions fail to result in adequate glycemic 
control (Rojas, Gomes, 2013). Krysiak et al. (2013b) 
demonstrated that metformin, when administered to 
simvastatin-treated patients with impaired fasting glucose 
levels, reduced HOMA-IR values by approximately 55% 
and A1C levels by 11% (Krysiak et al., 2013b). 
Pioglitazone – a thiazolidinedione that works by 
enhancing insulin sensitivity –improves A1C levels and 
is beneficial in reducing free fatty acid and triglyceride 
levels as well as increasing HDL cholesterol (Herz et al., 
2003; Kipnes et al., 2001). In a double-blinded study, 
pioglitazone alone and the combination of pioglitazone 
and simvastatin significantly improved glucose levels, 
insulin levels, and HOMA score. No such changes were 
seen in the simvastatin treatment group. In addition, it was 
reported that the pioglitazone-simvastatin combination 
was better for lowering the risk of cardiovascular events 
when compared to either of the drugs used alone (Forst 
et al., 2007). 
Hypertension and hypercholesterolemia are 
two major health issues that contribute to increased 
cardiovascular disease risk (Dalal et al., 2012), and 
the patients are commonly treated with statins and 
antihypertensive agents. As shown in Table V, the effect of 
combined simvastatin and antihypertensive medications 
has been investigated, and it was found that fasting plasma 
TABLE V - The effect of concurrent medications in combination with simvastatin (antihypertensive agents) 
Concurrent 
medication Subjects Country N
Mean follow-
up (month) Method
Outcome
Fasting 
glucose
Fasting 
insulin A1C
Insulin 
sensitivity Adiponectin
Perindopril or 
barnidipine 
(Derosa et al., 
2015)
Normocholes-
terolemic, 
hypertensive 
patients with 
nonalcoholic 
hepatic steatosis
Italy 149 12 Patients  were 
on perindopril 
5 mg/day or 
barnidipine 
20 mg/day for 
6 months and  
added with SIM 
20 mg/day for 
subsequent  
6 months
No 
significant 
changes in 
both group
No 
significant 
changes in 
both group
Not 
measured
Not 
measured
Increase in 
barnidipine 
+ SIM group 
compared to 
baseline 
(p < 0.05)
Losartan (Koh 
et al., 2004)
Hypercholes-
terolemia with 
hypertensive 
patients
Korea 47 3 treatment 
arm (2 months 
for each) 
and 2 washout 
period 
(2 months)
Patients were 
randomized 
receive either 
SIM 20 mg 
+ placebo, 
SIM 20 mg + 
losartan 100 mg 
or losartan 
100 mg + 
placebo daily
No 
significant 
changes in 
three group
No 
significant 
changes in 
three group
Not 
measured
Losartan 
+ SIM and 
losartan group 
significantly 
increase 
QUICKI
Increase in 
combination 
losartan + 
SIM group 
(p < 0.001) 
and losartan 
alone 
(p = 0.002)
Ramipril (Koh 
et al., 2005)
Hypercholes-
terolemia with 
T2DM
Korea 53 3 treatment 
arm (2 months 
for each) 
and 2 washout 
period 
(2 months)
Patients were 
randomized 
receive either 
SIM 20 mg 
+ placebo, 
SIM 20 mg + 
ramipril 
10 mg or 
ramipril 
10 mg + 
placebo daily
No 
significant 
changes in 
three group
No 
significant 
changes in 
three group
Not 
measured
Increase 
QUICKI 
in  SIM + 
ramipril 
group and 
ramipril 
alone group 
Increase in 
SIM + 
ramipril 
group and 
ramipril 
alone group 
Lisinopril 
(Kaminsky et 
al., 2010)
Atheros clerosis 
and moderate 
hypertensive 
Russia 32 24 Patients were 
randomized 
receive either 
lisinopril 
10-20 mg/day 
or lisinopril 
10-20 mg 
added with SIM 
20 mg daily
No 
significant 
changes in 
both group
Not 
measured
Not 
measured
Not 
measured
Not 
measured
Abbreviation: SIM (simvastatin)
N. R. Razali¹, H. Z. Huri¹,², L. Ibrahim³, S. R. Vethakkan³, B. M. Abdullah
Braz. J. Pharm. Sci. 2018;54(1):e17192Page 8 / 11
insulin and FBG levels were not affected by perindopril-
simvastatin or barnidipine-simvastatin regimens (Derosa 
et al., 2015). However, Koh et al. (2004) found that 
losartan alone or in combination with simvastatin resulted 
in a significant increase in insulin sensitivity and plasma 
adiponectin levels relative to the baseline, and that the 
difference was greater when compared to simvastatin alone 
(Koh et al., 2004).
CONCLUSIONS
In vitro studies have identified possible mechanisms 
by which simvastatin affects glucose metabolism. These 
include the inhibition of insulin secretion, possibly by 
decreasing GLUT2 activity, reducing ATP production, 
inhibiting L-type Ca2+ channels and decreasing cytosolic 
Ca2+ concentrations. Some studies have reported that 
simvastatin may impair glucose metabolism whereas 
other studies reported no effect or improvement of glucose 
metabolism.
Even though statins are beneficial in reducing 
the risk of cardiovascular events, its glycemic effect on 
patients should be monitored by periodically evaluating 
blood glucose levels regardless of whether the patients 
have diabetes or otherwise. Further studies are required 
to investigate the possible synergistic effects of statins 
with concurrent medication on glycemia, especially in 
patients with multiple comorbidities. Although the benefits 
of statins have been shown to outweigh its risks, it is 
important that glycemic control in patients is monitored 
for potential drug interactions between statins with the 
concurrent medications used. Besides that, further studies 
are recommended to determine whether or not the dose and 
duration of statin use could affect the glycemic control.
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